Results 51 to 60 of about 32,390 (296)

Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study

Patient Preference and Adherence, 2023
Chi Nguyen,1 Luke Bamber,2 Vincent J Willey,1 Thomas Evers,2 Thomas P Power,3 Judith J Stephenson1 1HealthCore, Inc., Wilmington, DE, USA; 2Bayer AG, Wuppertal, 42096, Germany; 3AIM Specialty Health, Chicago, IL, USACorrespondence: Chi Nguyen, HealthCore,
Nguyen C, Bamber L, Willey VJ, Evers T, Power TP, Stephenson JJ   +5 more
doaj  

Heart failure with preserved ejection fraction: A short review of diagnosis and management [PDF]

КардиоСоматика
Around 64 million persons in the world have heart failure (HF). HF patients with left ventricle ejection fraction (LVEF) of ≥50% are classified as having HF with preserved ejection fraction (HFpEF).
Sidhi Laksono, Prita Saskya Prameswari
doaj   +1 more source

Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.

PLoS ONE, 2021
Sudden death is the most common mode of mortality in patients with heart failure and preserved ejection fraction (HFpEF). Ventricular arrhythmias (VA) have been suspected as the etiology but the supporting evidence in patients with HFpEF is scarce.
Jae Hyung Cho, Derek Leong, Natasha Cuk, Joseph E Ebinger, Catherine Bresee, Sung-Han Yoon, Ashkan Ehdaie, Michael Shehata, Xunzhang Wang, Sumeet S Chugh, Eduardo Marbán, Eugenio Cingolani   +11 more
doaj   +1 more source

Phenotyping of Elderly Patients With Heart Failure Focused on Noncardiac Conditions: A Latent Class Analysis From a Multicenter Registry of Patients Hospitalized With Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The burden of noncardiovascular conditions is becoming increasingly prevalent in patients with heart failure (HF). We aimed to identify novel phenogroups incorporating noncardiovascular conditions to facilitate understanding and risk ...
Ryo Nakamaru, Yasuyuki Shiraishi, Nozomi Niimi, Takashi Kohno, Yuji Nagatomo, Makoto Takei, Takenori Ikoma, Kei Nishikawa, Munehisa Sakamoto, Shintaro Nakano, Shun Kohsaka, Tsutomu Yoshikawa   +11 more
doaj   +1 more source

Hemodynamic force analysis is not ready for clinical trials on HFpEF

Scientific Reports, 2022
Hemodynamic force analysis has been proposed as a novel tool for early detection of subclinical systolic dysfunction in heart failure with preserved ejection fraction (HFpEF). Here we investigated the ability of hemodynamic forces to discriminate between
P. Arvidsson, A. Nelsson, M. Magnusson, J. Smith, M. Carlsson, H. Arheden   +5 more
semanticscholar   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Non-invasive assessment of HFpEF in mouse models: current gaps and future directions

BMC Medicine, 2022
Heart failure (HF) with preserved ejection fraction (HFpEF) prevalence is increasing, and large clinical trials have failed to reduce mortality. A major reason for this outcome is the failure to translate results from basic research to the clinics ...
M. Villalba-Orero, P. García-Pavía, E. Lara-Pezzi   +2 more
semanticscholar   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Tetranectin as a potential biomarker in heart failure with ejection fraction >45%: A prospective cohort study

Romanian Journal of Internal Medicine
Heart failure (HF) with left ventricle ejection fraction (LVEF) >45% lacks reliable biomarkers for risk stratification complicating its management, as it encompasses both heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%) and mildly ...
Vulciu Paula Alexandra, Pilat Luminita, Varga Norberth-Istvan, Dascau Voicu, Popa Calin, Mot Maria-Daniela, Barata Paula Irina, Donath Miklos Imola, Puschita Maria   +8 more
doaj   +1 more source

Impact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Background. Cardiovascular diseases, including heart failure (HF) and heart failure with preserved ejection fraction (HFpEF), pose a global health challenge.
N.M. Kulaiets, V.M. Kulaiets, O.O. Tkachuk-Hryhorchuk, N.B. Nyshchuk-Oliinyk   +3 more
doaj   +1 more source